Intracellular β-tubulin/chaperonin containing TCP1-β complex serves as a novel chemotherapeutic target against drug-resistant tumors

Yuan Feng Lin, Wen Ping Tsai, Hon Ge Liu, Po Huang Liang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In the present study, treatment of HEK-293 cells with the synthetic small molecule N-iodoacetyl-tryptophan (I-Trp) at submicromolar concentrations efficiently induced cell apoptosis as judged from the accumulation of sub-G 0 cells and intracellular DNA fragmentation. Activation of all intracellular caspases, except caspase-1, was detected in I-Trp-treated cells. Proteomic analysis revealed that β-tubulin acted as a specific intracellular target of I-Trp. Protein fingerprinting analysis indicated that the Cys354 residue in the peptide fragment TAVCDIPPR of β-tubulin, which is located at the binding interface with chaperonin containing TCP1-β (CCT-β), was alkylated by I-Trp. Moreover, site-directed mutagenesis of. Cys354 (Cys-Ala) abolished the incorporation of I-Trp into β-tubulin, suggesting Cys354 is indeed the targeting site of I-Trp. Immunoprecipitation showed that the β-tubulin/CCT-β complex was constitutively formed but disrupted after treatment with I-Trp. Overexpression of the truncated β-tubulin (T351-S364) or treatment with I-Trp or the synthetic peptide Myr-TAVCDIPPRG caused more severe cell apoptosis in multidrug-resistant MES-SA/Dx5 cancer cells due to higher levels of CCT-β relative to wild-type MES-SA cancer cells. Silencing the expression of CCT-β rendered MES-SA/Dx5 cells less sensitive to I-Trp-induced apoptotic cell death. These findings suggest that the β-tubulin/CCT-β complex may serve as an effective chemotherapeutic target for treating clinical tubulin-binding agent-resistant or CCT-β-overexpressing tumors.

Original languageEnglish
Pages (from-to)6879-6888
Number of pages10
JournalCancer Research
Volume69
Issue number17
DOIs
Publication statusPublished - Sep 1 2009
Externally publishedYes

Fingerprint

Chaperonins
Tubulin
Tryptophan
Pharmaceutical Preparations
Neoplasms
Apoptosis
Caspase 1
Gastrin-Secreting Cells
Peptide Fragments
Peptide Mapping
HEK293 Cells
DNA Fragmentation
Caspases
Site-Directed Mutagenesis
Immunoprecipitation
Proteomics
Cell Death

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intracellular β-tubulin/chaperonin containing TCP1-β complex serves as a novel chemotherapeutic target against drug-resistant tumors. / Lin, Yuan Feng; Tsai, Wen Ping; Liu, Hon Ge; Liang, Po Huang.

In: Cancer Research, Vol. 69, No. 17, 01.09.2009, p. 6879-6888.

Research output: Contribution to journalArticle

@article{d9716cd8685f493b9afe9d87f79bf013,
title = "Intracellular β-tubulin/chaperonin containing TCP1-β complex serves as a novel chemotherapeutic target against drug-resistant tumors",
abstract = "In the present study, treatment of HEK-293 cells with the synthetic small molecule N-iodoacetyl-tryptophan (I-Trp) at submicromolar concentrations efficiently induced cell apoptosis as judged from the accumulation of sub-G 0 cells and intracellular DNA fragmentation. Activation of all intracellular caspases, except caspase-1, was detected in I-Trp-treated cells. Proteomic analysis revealed that β-tubulin acted as a specific intracellular target of I-Trp. Protein fingerprinting analysis indicated that the Cys354 residue in the peptide fragment TAVCDIPPR of β-tubulin, which is located at the binding interface with chaperonin containing TCP1-β (CCT-β), was alkylated by I-Trp. Moreover, site-directed mutagenesis of. Cys354 (Cys-Ala) abolished the incorporation of I-Trp into β-tubulin, suggesting Cys354 is indeed the targeting site of I-Trp. Immunoprecipitation showed that the β-tubulin/CCT-β complex was constitutively formed but disrupted after treatment with I-Trp. Overexpression of the truncated β-tubulin (T351-S364) or treatment with I-Trp or the synthetic peptide Myr-TAVCDIPPRG caused more severe cell apoptosis in multidrug-resistant MES-SA/Dx5 cancer cells due to higher levels of CCT-β relative to wild-type MES-SA cancer cells. Silencing the expression of CCT-β rendered MES-SA/Dx5 cells less sensitive to I-Trp-induced apoptotic cell death. These findings suggest that the β-tubulin/CCT-β complex may serve as an effective chemotherapeutic target for treating clinical tubulin-binding agent-resistant or CCT-β-overexpressing tumors.",
author = "Lin, {Yuan Feng} and Tsai, {Wen Ping} and Liu, {Hon Ge} and Liang, {Po Huang}",
year = "2009",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-08-4700",
language = "English",
volume = "69",
pages = "6879--6888",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Intracellular β-tubulin/chaperonin containing TCP1-β complex serves as a novel chemotherapeutic target against drug-resistant tumors

AU - Lin, Yuan Feng

AU - Tsai, Wen Ping

AU - Liu, Hon Ge

AU - Liang, Po Huang

PY - 2009/9/1

Y1 - 2009/9/1

N2 - In the present study, treatment of HEK-293 cells with the synthetic small molecule N-iodoacetyl-tryptophan (I-Trp) at submicromolar concentrations efficiently induced cell apoptosis as judged from the accumulation of sub-G 0 cells and intracellular DNA fragmentation. Activation of all intracellular caspases, except caspase-1, was detected in I-Trp-treated cells. Proteomic analysis revealed that β-tubulin acted as a specific intracellular target of I-Trp. Protein fingerprinting analysis indicated that the Cys354 residue in the peptide fragment TAVCDIPPR of β-tubulin, which is located at the binding interface with chaperonin containing TCP1-β (CCT-β), was alkylated by I-Trp. Moreover, site-directed mutagenesis of. Cys354 (Cys-Ala) abolished the incorporation of I-Trp into β-tubulin, suggesting Cys354 is indeed the targeting site of I-Trp. Immunoprecipitation showed that the β-tubulin/CCT-β complex was constitutively formed but disrupted after treatment with I-Trp. Overexpression of the truncated β-tubulin (T351-S364) or treatment with I-Trp or the synthetic peptide Myr-TAVCDIPPRG caused more severe cell apoptosis in multidrug-resistant MES-SA/Dx5 cancer cells due to higher levels of CCT-β relative to wild-type MES-SA cancer cells. Silencing the expression of CCT-β rendered MES-SA/Dx5 cells less sensitive to I-Trp-induced apoptotic cell death. These findings suggest that the β-tubulin/CCT-β complex may serve as an effective chemotherapeutic target for treating clinical tubulin-binding agent-resistant or CCT-β-overexpressing tumors.

AB - In the present study, treatment of HEK-293 cells with the synthetic small molecule N-iodoacetyl-tryptophan (I-Trp) at submicromolar concentrations efficiently induced cell apoptosis as judged from the accumulation of sub-G 0 cells and intracellular DNA fragmentation. Activation of all intracellular caspases, except caspase-1, was detected in I-Trp-treated cells. Proteomic analysis revealed that β-tubulin acted as a specific intracellular target of I-Trp. Protein fingerprinting analysis indicated that the Cys354 residue in the peptide fragment TAVCDIPPR of β-tubulin, which is located at the binding interface with chaperonin containing TCP1-β (CCT-β), was alkylated by I-Trp. Moreover, site-directed mutagenesis of. Cys354 (Cys-Ala) abolished the incorporation of I-Trp into β-tubulin, suggesting Cys354 is indeed the targeting site of I-Trp. Immunoprecipitation showed that the β-tubulin/CCT-β complex was constitutively formed but disrupted after treatment with I-Trp. Overexpression of the truncated β-tubulin (T351-S364) or treatment with I-Trp or the synthetic peptide Myr-TAVCDIPPRG caused more severe cell apoptosis in multidrug-resistant MES-SA/Dx5 cancer cells due to higher levels of CCT-β relative to wild-type MES-SA cancer cells. Silencing the expression of CCT-β rendered MES-SA/Dx5 cells less sensitive to I-Trp-induced apoptotic cell death. These findings suggest that the β-tubulin/CCT-β complex may serve as an effective chemotherapeutic target for treating clinical tubulin-binding agent-resistant or CCT-β-overexpressing tumors.

UR - http://www.scopus.com/inward/record.url?scp=70149124085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149124085&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-4700

DO - 10.1158/0008-5472.CAN-08-4700

M3 - Article

C2 - 19690144

AN - SCOPUS:70149124085

VL - 69

SP - 6879

EP - 6888

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -